Products MPDL3280A + mDCF
MPDL3280A + mDCF Phase 2 Completed ⚡ Active Jul 3, 2018 → Sep 20, 2023
About MPDL3280A + mDCF MPDL3280A + mDCF is a phase 2 stage product being developed by Roche for Anal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03519295. Target conditions include Anal Cancer.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT03519295 Phase 2 Completed Jul 3, 2018 Sep 20, 2023 Anal Cancer
Product Company Stage Hype Score aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib Johnson & Johnson Approved Acetaminophen Johnson & Johnson Phase 2 HRF2105 patch + Loxoprofen patch + placebo Jiangsu Hengrui Medicine Phase 2 Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation Jiangsu Hengrui Medicine Phase 1 Bupivacaine Liposome Injection Jiangsu Hengrui Medicine Approved Paracetamol injection + Normal Saline injection + Morhpine PCA Jiangsu Hengrui Medicine Phase 2/3 Bupivacaine Liposome Injection + Bupivacaine Hydrochloride Injection Jiangsu Hengrui Medicine Phase 2 Vandetanib + Capecitabine + Oxaliplatin + Bevacizumab AstraZeneca Phase 1 Org 28611 + morphine sulfate + Placebo Merck Phase 2 Pembrolizumab Merck Phase 2 Cetuximab + Mitomycin C + 5-Fluoruracil Merck Phase 1 Pembrolizumab + Paclitaxel + Carboplatin + Pembrolizumab Merck Phase 2 9-valent HPV vaccination Merck Phase 2 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Phase 2 Gardasil Merck Pre-clinical Sample collection Novartis Phase 2 Atezolizumab plus Tiraglolumab Roche Phase 2 panitumumab, mytomicin C, 5-FU, radiation Amgen Phase 2 oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloride Pfizer Phase 1 Ibuprofen 600 mg Immediate Release/Extended Release Caplet Pfizer Phase 3
Other Products from Roche